Success Stories: A Chinese Postdoctoral Fellow in Pennsylvania in the Field of Cell Biology Obtains EB-1A Petition Approval Just 9 Days after Filing

Client’s Testimonial:

“Thank you so much for your great guidance of my preparation the documents for petition letter. Your professional work in writing the recommendation letters and the petition letter are highly appreciated. I am so happy the 140 is approved with your help.”

On February 22^nd, 2017, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Cell Biology (Approval Notice).

General Field: Cell Biology

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: February 22^nd, 2017

Processing Time: 9 days (Premium Processing)

Case Summary:

The experienced team at North America Immigration Law Group (WeGreened.com) successfully helped a postdoctoral fellow navigate the challenging process of obtaining EB-1A (Alien of Extraordinary Ability) petition approval. The brief adjudication time of 9 days was the result of Premium Processing (PP), an option offered by the USCIS whereby the processing time is significantly reduced and petitioners need not wait longer than 15 days for action to be taken on their cases (the average timeline is between 4-9 months).

We commenced the process of preparing our client’s EB-1A petition package by carefully assessing his notable credentials. The doctoral degree he had attained from a top university in his birth country of China coupled with his extensive experience and expertise in the field of cell biology highlighted his value to the United States. We further demonstrated that our client’s specialized research in oncology and metastasis plays an important role in developing novel treatment methods for the most aggressive strains of cancer. We also proved to the USCIS that his work helps the US harness the spread of this life-threatening disease. Besides detailing our client’s research efforts, we also noted the following in his petition packet:

Our client’s publication record of 22 peer-reviewed scientific articles and his citation count of 143 citations at the time of filing established him as a frontrunner in the domain of cell biology.
One of the highlights of his EB-1A petition was the outstanding 150 reviews he had conducted over the span of his research career. Since only top-level experts in their field are invited to assess the work of others, this was an accomplishment which the USCIS could not ignore.
We also incorporated 6 recommendation lettersinto our client’s EB-1Apetition packet to establish him as a leader in the field of cell biology. These letters were contributed by other influential experts in the field. One such letter stated: “As is often the case with this type of research, the impact of [Client’s] contributions extends far beyond the scholastic sphere into clinical therapeutics, drug development, medical diagnostics and related areas, all of which benefit immensely from the research set forth by [Client].” These words of appreciation played a role in setting the tide in favor of our client and convinced the USCIS that his continued presence in the United States benefits the nation as a whole.

We congratulate our client for securing a highly sought-after EB-1A approval notice and we wish him the best as he continues to progress the field of cell biology in the US. We also assure him of our unwavering support as we work diligently on his I-485 application (the final step in the green card process).

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.